Table 1. Clinical characteristics, genomic findings and histology data for group 1.
| Patient | Clinical characteristics | Genomic findings | Histology | ||||||||||
| Sex | Age at diagnosis (months) | INSS stage | Localisation | Metastasis at diagnosis | MIBG uptake | Urinary catechol | Initial treatment | Relapse (months) | Outcome (FU months) | Amplicons (cytogenetic band) | Segmental alterations | Grade of differentiation | |
| NB0384 | M | 23 | 4 | Abd | B, M | Y | H | IM | No | CR(121) | 11q13 | −1p, −3p, −11q, +17q | P. diff NB |
| NB0040 | M | 54 | 4 | Adr | B, M, DLN | Y | H | IM | Ms(25) | DOD(75,5) | 11q13, 17q25 | −11q, −16p, −16q, +17q | P. diff NB |
| NB0791 | M | 18 | 3 | Cervical | LLN | No | Nl | CT-S | No | CR(44) | 16q22 | numerical | Undiff NB |
| NB0760 | F | 17 | 4 | Abd | DLN | Y | H | IM | No | CR(44) | 12q13_14, 12q24 | numerical | P. diff NB |
| NB0830 | F | 22 | 2b | Abd median | none | No | Nl | S | No | CR(27) | 12q13_14 | −22q | Diff NB |
| NB0037 | M | 55 | 3 | Abd lumbar | LLN | Y | H | S-CT | L(7) | CR(129) | 12q13_15, 21q22 | +1p, +13q, +17q | P. diff NB |
| NB0072 | F | 51 | 4 | Adr | B, M, DLN | Y | na | CT-S | No | Al(31) | 7q21 | −3p, +18 pq | Undiff NB |
| NB0039 | M | 67 | 4 | Adr | Lung | No | Nl | IM | Ms+L(14,5) | DOD(19) | 12q12, 12q13_15 | +1p, +4q | P.diff NB |
M, male; F, female; Adr, adrenal; Abd, abdominal; B, bone; M: bone marrow; DLN: distant lymph nodes; LLN: local lymph nodes; Ms, Metastatic relapse; L, Local relapse; MIBG, metaiodobenzylguanidine uptake at primary tumour site; Y, yes; H, high secretion of urinary catecholamines; Nl, normal secretion of urinary catecholamines; IM, intensive multimodality; S: surgery; CT, chemotherapy; DOD, dead of disease; Al, alive status unknown; CR, complete remission; NB, neuroblastoma; Undiff., undifferentiated; P.diff., poorly differentiated; Diff, differentiating; na, not available.